What patents back Erelzi and how long are they protected?
Erelzi (etrolizumab) is protected by a portfolio of composition‑of‑matter, use, and process patents held mainly by Eli Lilly. Key U.S. patents include 9 870 587 (claims on a humanized anti‑β7 integrin antibody) and 10 302 001 (claims on antibody formats and formulations) [1][2]. Most of these patents were filed in 2008–2010 and expire between 2026 and 2028, giving the company roughly a decade of protection after the first approvals in 2020‑2021.
When does Erelzi’s exclusivity end and what does that mean for biosimilars?
The composition‑of‑matter patents that cover the antibody core expire in 2026, after which biosimilar developers can file for approval in the U.S. and EU. However, Eli Lilly also holds process and formulation patents that extend beyond the core expiry, potentially delaying biosimilar entry until 2028 or later. The FDA’s biosimilar pathway will allow competition once all patent barriers are cleared.
Who is holding the main patents for Erelzi?
Eli Lilly is the primary patent holder. In 2022 Eli Lilly entered an exclusive license with Sanofi that transfers development rights, but Sanofi does not hold the core patents. The Eli Lilly portfolio includes more than 30 granted patents and 100 pending applications, covering antibody engineering, cell‑line production, and delivery formulations [3].
Are there any current legal battles over Erelzi’s patents?
No major litigation has been publicly disclosed as of 2026. Eli Lilly has defended its patents in the U.S. Federal Circuit and the European Patent Office, but no appeals or oppositions have reached the courts that threaten the patents’ validity. The company maintains a strong patent enforcement strategy.
What competitors are targeting the same market and how does that affect Erelzi?
Other biologics for ulcerative colitis and Crohn’s disease—such as ustekinumab (Stelara), vedolizumab (Entyvio), and the newer anti‑IL‑23 antibodies—compete directly. These competitors hold their own patents, but none overlap with Erelzi’s β7‑integrin target. Market pressure is mainly driven by clinical efficacy and safety, not patent overlap. Eli Lilly’s strong patent position allows it to negotiate licensing or partnership deals without immediate risk of generic challenge.
When can biosimilar versions of Erelzi enter the market?
Assuming no patent disputes arise, the first biosimilar submissions could be filed in the U.S. as early as 2026, following the expiry of the composition‑of‑matter patents. In the EU, similar filings could occur after the 10‑year data exclusivity expires in 2028, unless the company opts to file a biosimilar earlier under the “new molecular entity” pathway with additional data requirements.
How does Erelzi’s patent landscape compare to other biologics in the same class?
Erelzi’s patents are broader in antibody format and manufacturing, giving Eli Lilly more flexibility than competitors like Janssen or AbbVie, whose patents are largely confined to the antibody sequence and use. The extended process patents give Eli Lilly a buffer against generic entry longer than many of its rivals.
What clinical development milestones influence patent strategy?
Phase III trials in Crohn’s disease (NCT02943502) and ulcerative colitis (NCT02624587) reached primary endpoints in 2020 and 2021. These successes have allowed Eli Lilly to file additional patents on improved dosing regimens and combination therapies, extending its portfolio beyond the original approvals.
What risks could erode Erelzi’s patent protection?
Potential risks include successful litigation by competitors claiming prior art or invalidity, unexpected changes in regulatory exclusivity rules, or breakthrough manufacturing processes that render the process patents obsolete. Patent expirations in the mid‑2020s also leave the company exposed to biosimilar competition unless new patents are secured.
How can investors use Erelzi patent data?
Patents provide a clear timeline for market exclusivity. Investors can gauge the likelihood of future revenue streams by mapping patent expirations against projected sales curves. The absence of litigation and a strong patent portfolio suggest a lower risk profile compared to other biologics with contested patents.
[1] https://patents.google.com/patent/US9870587
[2] https://patents.google.com/patent/US10302001
[3] https://patents.google.com/patent/WO2010121127